Ser357
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser357  -  PSEN1 (human)

Site Information
PHRstPEsRAAVQEL   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448563
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 13 , 14 ) , immunoprecipitation ( 13 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , mutation of modification site ( 12 , 13 , 14 ) , peptide sequencing ( 14 )
Disease tissue studied:
lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 ) , non-small cell lung cancer ( 3 , 4 , 6 , 7 , 8 ) , non-small cell lung adenocarcinoma ( 3 , 4 , 5 , 6 , 7 , 8 ) , non-small cell large cell lung carcinoma ( 6 ) , non-small cell squamous cell lung carcinoma ( 5 ) , small-cell lung cancer ( 1 , 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 12 , 13 ) , A549 (pulmonary) ( 3 ) , Cal-12T (pulmonary) ( 7 ) , Calu-3 (pulmonary) ( 4 ) , DMS53 (pulmonary) ( 2 ) , DMS79 (pulmonary) ( 1 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 9 ) , Flp-In T-Rex-293 (epithelial) ( 9 ) , HCC15 (pulmonary) ( 5 ) , HCC44 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 4 ) , HEK293T (epithelial) ( 14 ) , HeLa (cervical) ( 10 ) , Jurkat (T lymphocyte) ( 11 ) , LOU-NH91 (squamous) ( 5 ) , lung ( 1 , 2 , 3 , 4 , 5 , 6 , 7 ) , NCI-H128 (pulmonary) ( 1 ) , NCI-H1355 (pulmonary) ( 3 ) , NCI-H1417 (pulmonary) ( 1 ) , NCI-H1437 (pulmonary) ( 7 ) , NCI-H1650 (pulmonary) ( 4 ) , NCI-H1666 (pulmonary) ( 7 ) , NCI-H1703 (squamous) ( 5 ) , NCI-H1781 (pulmonary) ( 6 ) , NCI-H1792 (pulmonary) ( 3 ) , NCI-H1975 (pulmonary) ( 4 ) , NCI-H2073 (pulmonary) ( 5 ) , NCI-H209 (pulmonary) ( 1 ) , NCI-H2106 (pulmonary) ( 4 ) , NCI-H2228 (pulmonary) ( 6 , 8 ) , NCI-H23 (pulmonary) ( 3 ) , NCI-H2342 (pulmonary) ( 5 ) , NCI-H2405 (pulmonary) ( 7 ) , NCI-H3122 (pulmonary) ( 6 ) , NCI-H441 (pulmonary) ( 3 ) , NCI-H446 (pulmonary) ( 2 ) , NCI-H524 (pulmonary) ( 1 ) , NCI-H526 (pulmonary) ( 2 ) , NCI-H661 (pulmonary) ( 6 ) , NCI-H69 (pulmonary) ( 2 ) , NCI-H82 (pulmonary) ( 2 )

Upstream Regulation
Putative in vivo kinases:
GSK3B (human) ( 12 , 13 )
Kinases, in vitro:
GSK3B (human) ( 13 , 14 )
Treatments:
GSK-3_inhibitor_VIII ( 13 ) , okadaic_acid ( 13 )

Downstream Regulation
Effects of modification on PSEN1:
intracellular localization ( 12 ) , molecular association, regulation ( 12 , 14 ) , protein conformation ( 13 )
Effects of modification on biological processes:
cell growth, altered ( 13 )
Induce interaction with:
CTNNB1 (human) ( 14 )
Inhibit interaction with:
CDH2 (human) ( 12 ) , CTNNB1 (human) ( 12 , 13 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT
Curated Info

9

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

10

Zhou J (2010) CST Curation Set: 10690; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (ST*P) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (ST*P) Immunoaffinity Beads Cat#: 5756
Curated Info

11

Possemato A (2008) CST Curation Set: 5275; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995
Curated Info

12

Uemura K, et al. (2007) GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem 282, 15823-32
17389597   Curated Info

13

Prager K, et al. (2007) A structural switch of presenilin 1 by glycogen synthase kinase 3beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling. J Biol Chem 282, 14083-93
17360711   Curated Info

14

Kirschenbaum F, Hsu SC, Cordell B, McCarthy JV (2001) Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling. J Biol Chem 276, 7366-75
11104755   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.